Incannex update on ihl-42x drug candidate in phase 2/3 clinical trial in obstructive sleep apnea

Melbourne, australia and new york, dec. 06, 2023 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (‘incannex' or the ‘company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to provide the following update on its proprietary ihl-42x drug candidate.
IXHL Ratings Summary
IXHL Quant Ranking